Lung Cancer
Volume 71, Issue 3 , Pages 328-332, March 2011

Assessment of lung-cancer mortality reduction from CT Screening

  • Claudia I. Henschke

      Affiliations

    • Mount Sinai School of Medicine, New York, NY, United States
    • Biodesign Institute, Arizona State University, Tempe, AZ, United States
    • Corresponding Author InformationCorresponding author at: Department of Radiology, Box 1234, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029, United States. Tel.: +1 212 241 2821; fax: +1 212 241 9655.
  • ,
  • Paolo Boffetta

      Affiliations

    • Mount Sinai School of Medicine, New York, NY, United States
    • Biodesign Institute, Arizona State University, Tempe, AZ, United States
    • International Prevention Research Institute, Lyon, France
  • ,
  • Olga Gorlova

      Affiliations

    • MD Anderson Cancer Center, Houston, TX, United States
  • ,
  • Rowena Yip

      Affiliations

    • Mount Sinai School of Medicine, New York, NY, United States
  • ,
  • John O. DeLancey

      Affiliations

    • American Cancer Society, Atlanta, GA, United States
  • ,
  • Millennia Foy

      Affiliations

    • MD Anderson Cancer Center, Houston, TX, United States

Received 28 September 2010; received in revised form 28 October 2010; accepted 31 October 2010. published online 20 December 2010.

Abstract 

Background

CT screening has been shown to increase lung cancer curability and we now assess the corresponding reduction in lung cancer mortality.

Methods

Lung-cancer mortality in a cohort of 7995 smokers who underwent CT screening for lung cancer in New York State (NYS) was compared with two unscreened cohorts (CPS-II and CARET). The standardized mortality ratio (SMR) of observed to expected lung cancer deaths for NYS was jointly adjusted for age, sex, and smoking history. As more current NYS smokers might have quit as a result of the screening, thus reducing deaths from lung cancer, another analysis was restricted to those participants smoking at entry and still smoking 6 years later.

Results

The SMR was 64/99.8=0.64 (P=0.84×10−4) and 28/77.6=0.36 (P=0.83×10−10), showing a significant reduction in deaths from lung cancer of 36% and 64% for CPS-II and CARET, respectively. Considering participants who were smoking at entry and still smoking 6 years later, the SMR using CPS-II rates was 29/49.1=0.59 (P=0.001) and using CARET rates it was 21/57.4=0.37 (P=0.31×10−7).

Conclusions

CT screening significantly reduces lung-cancer mortality.

Keywords: Lung cancer, CT screening, Mortality reduction, CARET, CPS-II

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(10)00539-8

doi:10.1016/j.lungcan.2010.10.025

Lung Cancer
Volume 71, Issue 3 , Pages 328-332, March 2011